Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in High PD-L1, Chemotherapy-Naïve Stage IV NSCLC
NCT05047250Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jun 2022; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05047250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047250.